These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 27815407)

  • 1. CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.
    Pignolet B; Schwab N; Schneider-Hohendorf T; Bucciarelli F; Biotti D; Averseng-Peaureaux D; Outteryck O; Ongagna JC; de Sèze J; Brochet B; Ouallet JC; Debouverie M; Pittion S; Defer G; Derache N; Hautecoeur P; Tourbah A; Labauge P; Castelnovo G; Clavelou P; Berger E; Pelletier J; Rico A; Zéphir H; Laplaud D; Wiertlewski S; Camu W; Thouvenot E; Casez O; Moreau T; Fromont A; Vukusic S; Papeix C; Vermersch P; Comabella M; Lebrun-Frenay C; Wiendl H; Brassat D;
    Neurology; 2016 Dec; 87(23):2491-2494. PubMed ID: 27815407
    [No Abstract]   [Full Text] [Related]  

  • 2. CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.
    Lieberman LA; Zeng W; Singh C; Wang W; Otipoby KL; Loh C; Plavina T; Gorelik L; Ransohoff RM; Cahir-McFarland E
    Neurology; 2016 Jan; 86(4):375-81. PubMed ID: 26718566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy.
    Warnke C; Wijburg MT; Hartung HP; Killestein J; Adams O; Wattjes MP
    J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1092-1094. PubMed ID: 28490505
    [No Abstract]   [Full Text] [Related]  

  • 4. Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals.
    Schwab N; Schneider-Hohendorf T; Pignolet B; Bucciarelli F; Scandella L; Ciron J; Biotti D; Lebrun-Frenay C; Mathey G; Clavelou P; Pelletier J; Ostkamp P; Meinl I; Windhagen S; Klotz L; Gross CC; Meuth SG; Deisenhammer F; Brassat D; Wiendl H;
    Neurology; 2019 Sep; 93(12):550-554. PubMed ID: 31439633
    [No Abstract]   [Full Text] [Related]  

  • 5. PML risk stratification using anti-JCV antibody index and L-selectin.
    Schwab N; Schneider-Hohendorf T; Pignolet B; Spadaro M; Görlich D; Meinl I; Windhagen S; Tackenberg B; Breuer J; Cantó E; Kümpfel T; Hohlfeld R; Siffrin V; Luessi F; Posevitz-Fejfár A; Montalban X; Meuth SG; Zipp F; Gold R; Du Pasquier RA; Kleinschnitz C; Jacobi A; Comabella M; Bertolotto A; Brassat D; Wiendl H
    Mult Scler; 2016 Jul; 22(8):1048-60. PubMed ID: 26432858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.
    Pitarokoili K; Gold R
    Nat Rev Neurol; 2017 Dec; 13(12):710-712. PubMed ID: 29146954
    [No Abstract]   [Full Text] [Related]  

  • 7. Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature.
    Zhang Y; Wright C; Flores A
    J Med Case Rep; 2018 Jul; 12(1):187. PubMed ID: 29960601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - NO.
    Enzinger C
    Mult Scler; 2017 May; 23(6):767-770. PubMed ID: 28287038
    [No Abstract]   [Full Text] [Related]  

  • 9. Evolution of MRI appearances due to progressive multifocal leucoencephalopathy following natalizumab treatment for multiple sclerosis.
    Campbell S; Kanodia AK; O'Riordan J
    BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25878241
    [No Abstract]   [Full Text] [Related]  

  • 10. [Natalizumab can induce progressive multifocal leucoencephalopathy].
    Theódórsdóttir A; Blaabjerg M; Falah M
    Ugeskr Laeger; 2014 Aug; 176(35):. PubMed ID: 25293706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - YES.
    Yap SM; McGuigan C
    Mult Scler; 2017 May; 23(6):765-767. PubMed ID: 28287039
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.
    Hoepner R; Kolb EM; Dahlhaus S; Hellwig K; Adams O; Kleiter I; Salmen A; Schneider R; Lukas C; Chan A; Berger JR; Gold R
    Mult Scler; 2017 May; 23(6):830-835. PubMed ID: 27600113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen.
    Hervás JV; Presas-Rodríguez S; Crespo-Cuevas AM; Canento T; Lozano-Sánchez M; Massuet-Vilamajó A; Ramo-Tello C
    Neurodegener Dis Manag; 2015 Oct; 5(5):399-402. PubMed ID: 26517599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab risk stratification: role of a two- step anti-JCV antibody assay.
    O'Connor PW
    Can J Neurol Sci; 2012 Sep; 39(5):670-5. PubMed ID: 22931715
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk factors for rare diseases can be risky to define: PML and natalizumab.
    Major EO; Douek DC
    Neurology; 2013 Sep; 81(10):858-9. PubMed ID: 23925759
    [No Abstract]   [Full Text] [Related]  

  • 16. The 'across the pons' sign: A possible novel radiographic finding in natalizumab-associated progressive multifocal leukoencephalopathy.
    Budhram A; Pelikan JB; Kremenchutzky M; Sharma M
    J Neurol Sci; 2017 Apr; 375():304-306. PubMed ID: 28320156
    [No Abstract]   [Full Text] [Related]  

  • 17. PML in natalizumab-treated multiple sclerosis: Modeling errors and risk miscalculations.
    Mowry EM; McArthur JC
    Neurology; 2017 Mar; 88(12):1110-1111. PubMed ID: 28228562
    [No Abstract]   [Full Text] [Related]  

  • 18. Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks.
    Maloney E; Molloy A; Al Hussona M; O'Donnell L; Killeen R; McGuigan C
    J Neurol; 2017 Feb; 264(2):401-403. PubMed ID: 28039520
    [No Abstract]   [Full Text] [Related]  

  • 19. Should we broaden indications for anti-JCV antibody tests in multiple sclerosis patients? No.
    Labauge P
    Rev Neurol (Paris); 2017 Dec; 173(10):614-615. PubMed ID: 29102328
    [No Abstract]   [Full Text] [Related]  

  • 20. Considerations for characterizing the risk of PML in natalizumab-treated patients.
    Koendgen H; Ho PR; Chang I
    Mult Scler Relat Disord; 2016 Sep; 9():121. PubMed ID: 27645357
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.